In the landscape of modern medicine, few challenges are as persistent as breast cancer. Affecting approximately one in eight women in the United States, the disease remains a significant global health burden. While landmark discoveries—most notably the BRCA1 and BRCA2 genes—have revolutionized our understanding of hereditary risk, a glaring gap remains: many families with a documented history of breast cancer do not carry these well-known mutations.
To bridge this chasm, Dr. Jennifer Asmussen, a computational biologist and Faculty Instructor in the Department of Molecular and Human Genetics at Baylor College of Medicine, has unveiled a pioneering study published in The American Journal of Human Genetics (AJHG). Her research, titled "Ultra-rare functional variants reveal early-onset breast cancer risk genes and pathways in the UK Biobank and All of Us Research program," leverages the power of big data and evolutionary biology to redefine how we identify the genetic drivers of early-onset breast cancer.
Main Facts: The Power of Population-Scale Sequencing
The core of Dr. Asmussen’s work lies in the utilization of massive, population-scale biobanks. By integrating high-throughput exome and genome sequencing with matched electronic health records, researchers can now peer into the genetic architecture of diseases with unprecedented clarity.
Historically, Genome-Wide Association Studies (GWAS) have focused on common genetic variants—small, incremental changes that, when aggregated, offer a "polygenic risk score." While useful, these common variants often have low individual effect sizes. Dr. Asmussen’s approach pivots toward "ultra-rare" variants. These mutations are far less frequent in the general population but carry a significantly higher weight in terms of disease risk.
By applying the "Evolutionary Action" (EA) framework—developed by the Lichtarge Lab at Baylor—Dr. Asmussen has created a methodology that identifies specific genes and biological pathways enriched for these high-impact, rare mutations. This approach allows researchers to look beyond the "usual suspects" of hereditary cancer and uncover novel genetic pathways that contribute to tumor development.
A Chronological Journey: From Bench to Biobank
Dr. Asmussen’s career trajectory is as unique as the genomic pathways she studies. Her journey is not a straight line, but a deliberate exploration of the intersection between biological sciences, administration, and computational analysis.
Early Career and Academic Foundation
Before becoming a computational biologist, Dr. Asmussen spent time as a bench scientist, gaining an intimate understanding of the physical processes within cells. However, she recognized early on that the sheer volume of data being generated in the biological sciences required a new set of tools.
The Administrative Bridge
Perhaps her most unconventional step was a tenure in academic administration at the University of Houston, where she managed undergraduate research programs. While this might seem removed from genomic sequencing, Dr. Asmussen cites this period as foundational. It was here that she honed the critical communication, writing, and project management skills that allow her to navigate the complex, multi-stakeholder environment of modern large-scale research.
The Computational Pivot
Transitioning into her role as a postdoctoral fellow and subsequently a Faculty Instructor, Dr. Asmussen merged her biological expertise with computational prowess. By joining the Lichtarge Lab, she gained access to the EA-Pathways algorithm—a sophisticated tool that uses the evolutionary history of proteins to predict which mutations are likely to be functionally deleterious.
Recent Breakthroughs
In the months leading up to the publication of her recent AJHG paper, Dr. Asmussen dedicated her efforts to synthesizing data from the UK Biobank and the All of Us Research Program. The successful identification of novel risk genes marks the culmination of years of data curation, algorithmic refinement, and iterative testing.
Supporting Data: Why "Evolutionary Action" Matters
The strength of Dr. Asmussen’s research lies in the statistical robustness provided by the EA-Pathways algorithm. In traditional genetic studies, researchers often rely on a "control group" of healthy individuals to compare against the patient cohort. However, in the context of cancer, this is problematic: a "healthy" person in a control group might simply be a "case-in-waiting," harboring genetic predispositions that have not yet manifested as clinical symptoms.
Bypassing the Control Group
EA-Pathways bypasses the need for perfectly matched controls by relying on the statistical properties of the Evolutionary Action variant impact score. This score measures the extent to which a genetic mutation disrupts a protein’s function, based on its evolutionary conservation.
- High Conservation: If a position in a protein has remained unchanged for millions of years of evolution, a mutation there is likely to be damaging.
- Functional Impact: By focusing on these damaging mutations, the algorithm can isolate risk genes even in smaller cohorts, effectively filtering out the "noise" of neutral genetic variation.
This innovation allows researchers to identify high-to-moderate-impact risk genes that were previously hidden in the background of human genomic variation.
Official Responses: The Impact on the Scientific Community
The publication of this research has been met with enthusiasm within the human genetics community. Editors at The American Journal of Human Genetics have highlighted the work as a model for how biobank data can be translated into actionable clinical insights.
Implications for Clinical Practice
The immediate goal of this work is to provide a shortlist of candidate risk genes that can be validated by experimental collaborators in a laboratory setting. Once validated, these genes could potentially be incorporated into clinical genetic testing panels. For a woman with a strong family history of breast cancer who tests negative for BRCA mutations, these newly discovered genes could provide the answers that families have been seeking for decades.
A Global Perspective
Dr. Asmussen emphasizes that the long-term objective is to move beyond current limitations in demographic representation. By utilizing the All of Us Research Program, which prioritizes diversity in its participant base, her work aims to uncover risk genetics that are relevant across different ancestry groups. This is a critical step toward health equity in oncology, ensuring that the benefits of precision medicine are not limited to a single demographic.
Implications: The Future of Personalized Medicine
The ripple effects of this research extend far beyond the study of breast cancer. The methodology established by Dr. Asmussen—using EA-Pathways to identify rare, functional variants—is highly adaptable.
Broad Applicability
"EA-Pathways… can and should be applied to other cancers, diseases, and complex phenotypes," Dr. Asmussen notes. From neurodegenerative disorders to cardiovascular diseases, the ability to prioritize genetic variants based on their evolutionary importance offers a universal toolkit for disease research.
Cultivating the Next Generation of Scientists
For trainees and young researchers, Dr. Asmussen’s path serves as a powerful testament to the value of diverse experience. She encourages those in the field to "follow your heart, trust your instinct, don’t be afraid to take the road less traveled, and never stop learning." Her story illustrates that a successful career in science is built as much on adaptability and soft skills—communication, program management, and interdisciplinary collaboration—as it is on technical proficiency.
Life Outside the Lab: The Human Element
While her professional life is defined by the rigorous, often abstract world of algorithms and exome sequencing, Dr. Asmussen’s life outside the lab is grounded in the tangible. A mother of two, she spends much of her time on the sidelines of youth volleyball games or watching little league baseball.
Perhaps surprisingly, she draws a parallel between her home life and her work. During the pandemic, she developed a passion for cooking, which she describes as an "experimental" process. "It gives me the opportunity to be creative and to share my creations with others," she says. Whether she is tweaking a recipe in the kitchen or adjusting a hyperparameter in a genomic algorithm, the spirit of curiosity remains the same.
This balance between the high-stakes world of medical research and the simple joys of family and creativity defines Dr. Asmussen’s approach to science. It is a reminder that behind the complex datasets and high-impact publications are real people, working to solve the most pressing challenges of our time, driven by a simple, human desire to improve the lives of those around them.
As the scientific community continues to digest the findings of her latest paper, one thing is clear: the road to understanding the genetic origins of breast cancer has just become a little shorter, thanks to the intersection of big data, evolutionary biology, and a researcher who isn’t afraid to take the path less traveled.
About the Author
